IMUX
Immunic (IMUX)
$57
About Immunic (IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
Details
Daily high
$0.59
Daily low
$0.55
Price at open
$0.58
52 Week High
$1.39
52 Week Low
$0.55
Market cap
68.9M
Dividend yield
0.00%
Volume
2.3M
Avg. volume
1.4M
P/E ratio
-.66
Immunic News
Details
Daily high
$0.59
Daily low
$0.55
Price at open
$0.58
52 Week High
$1.39
52 Week Low
$0.55
Market cap
68.9M
Dividend yield
0.00%
Volume
2.3M
Avg. volume
1.4M
P/E ratio
-.66